ARA-290 Dosage Guide

What Is the Standard ARA-290 Dose?

Clinical Phase II trials established 4 mg once daily as the standard dose. This dose was selected based on pharmacokinetic and pharmacodynamic studies determining optimal innate repair receptor (IRR) pathway activation. The 4 mg dose was used across all major clinical populations: diabetic peripheral neuropathy, sarcoidosis, and idiopathic small fiber neuropathy. Results showed consistent efficacy with this standardized dose.

The 4 mg daily dose is typically self-administered via subcutaneous injection. Patients can inject at various sites: lower abdomen, lateral thigh, or outer upper arm. Self-administration is straightforward after initial healthcare provider training, allowing outpatient treatment without clinic visits.

Dose Justification: Pharmacokinetics and Response

Absorption and Half-Life
Following subcutaneous injection, ARA-290 is absorbed over 2-4 hours, reaching peak plasma concentrations by 4-6 hours. The approximate plasma half-life is 24 hours, meaning once-daily dosing maintains therapeutic concentrations continuously. After 3-4 days of daily dosing, steady-state plasma concentrations are achieved. This steady-state maintenance is critical for the sustained IRR activation required for tissue repair.

Dose-Response Relationship
Preclinical studies and early clinical data suggest dose-response relationship, but with diminishing returns at higher doses. The 4 mg dose was selected as the optimal point on the dose-response curve: sufficient for maximal IRR activation and tissue repair effects, without increased adverse events seen at doses above 5-6 mg. Going below 2 mg shows reduced efficacy in preclinical models.

Clinical Efficacy at 4 mg
Phase II trial results using 4 mg daily showed: 30-50% pain reduction in neuropathy patients, 25-45% IENF (small nerve fiber) density improvements, and 30-60% reductions in inflammatory markers (TNF-α, IL-6). These effect sizes were consistent across all major trial populations, suggesting 4 mg achieves near-maximal pharmacodynamic response.

Lower Dose Alternatives: 2-3 mg Considerations

Tolerability and Individual Variation
While formal trials used 4 mg exclusively, some practitioners report using 2-3 mg doses for patients who are: extremely sensitive to injectable medications, have very high baseline frailty, or are starting conservatively. However, efficacy data at doses below 4 mg is limited. Anecdotal reports suggest 3 mg produces roughly 70-80% of 4 mg benefits, while 2 mg produces 50-60%.

When Lower Doses May Apply
Very elderly patients (80+), patients with multiple comorbidities significantly limiting regenerative capacity, or those with prior adverse reactions to injectable peptides might theoretically benefit from dose-conservative approaches. However, this remains clinical judgment rather than evidence-based guidance, as formal dose-escalation studies are lacking.

Risk-Benefit Analysis
Given ARA-290's excellent safety profile at 4 mg with minimal adverse events, most clinical decisions favor standard 4 mg dosing unless specific contraindications exist. Conservative dosing sacrifices efficacy without clear safety benefit, as adverse events are rare at standard dosing.

Dose Adjustment Strategies: When and How

Response-Based Adjustment
Clinical trials used fixed 4 mg dosing throughout the 28-day cycle. However, some practitioners report adjusting based on early response: if weeks 1-3 show robust improvements with excellent tolerability, continuing 4 mg. If minimal improvement by week 3, discontinuing rather than dose-escalating (since non-responders are unlikely to respond to higher doses). This response-based approach is pragmatic rather than evidence-based.

Theoretical Dose Escalation
Some practitioners hypothesize that non-responders might benefit from 5-6 mg dosing, though formal data supporting escalation is absent. Theoretical risks of escalation include increased systemic inflammatory stimulation or injection site reactions. Without trial data, escalation remains speculative.

Extended Duration vs. Higher Dose
Rather than increasing daily dose, extending the treatment cycle (from 28 days to 8 weeks) may be more physiologically rational. Extended duration maintains tissue IRR saturation longer, potentially improving outcomes in severe cases. This approach is supported by tissue remodeling kinetics, whereas dose escalation is not.

Administration Method: Subcutaneous Self-Injection

Injection Sites and Rotation
ARA-290 is administered via subcutaneous (SC) injection, meaning the needle penetrates through skin into the subcutaneous fat layer below. Optimal injection sites include: lower abdomen (below navel, 2-3 inches lateral from midline), lateral thigh (outer aspect, mid-thigh level), or outer upper arm. Rotating injection sites prevents localized tissue irritation and ensures adequate absorption from fresh tissue.

Injection Technique and Needle Size
Standard subcutaneous injection uses 25-27 gauge needles (small gauge, minimal discomfort). Needle length is typically 5/8 inch. After cleaning the injection site with an alcohol wipe, pinch the skin to create a small fold, insert the needle at 45-90 degree angle (perpendicular insertion is easier for most patients), and inject slowly over 5-10 seconds to allow tissue absorption.

Post-Injection Care
After injection, light pressure on the site for 10-15 seconds can reduce bruising risk. Most injection site reactions (mild redness, small bruises) resolve within 1-2 hours. Applying ice immediately post-injection can reduce inflammation if significant reaction occurs, though this is rarely necessary.

Patient Training Requirements
Most patients successfully self-inject ARA-290 after a single healthcare provider demonstration. Injection anxiety diminishes rapidly after the first few injections. Detailed written instructions with illustrations are helpful. Some providers recommend the first injection be done in a clinical setting under supervision, though this is not mandatory for safety.

Frequency: Why Once Daily?

Pharmacokinetic Optimization
Once-daily dosing maintains therapeutic plasma concentrations continuously due to the ~24-hour half-life. Twice-daily dosing would cause peak plasma concentrations 2x higher than necessary, without proportionally greater tissue repair effects. Once daily balances efficacy with practical convenience.

Tissue Saturation and Continuous Signaling
Innate repair receptor signaling requires sustained, not pulsatile, activation for optimal tissue remodeling. Once-daily dosing maintains constant IRR occupancy and downstream signaling. Pulsatile (twice-daily or less frequent) dosing would result in periods of inadequate IRR activation and less optimal tissue repair.

Practical Compliance Advantages
Once-daily injection has major compliance advantages over twice-daily regimens. Patient adherence is typically 85-95% with once-daily dosing versus 60-75% with twice-daily. Better adherence improves overall outcomes and makes once-daily dosing pragmatically optimal beyond the pure pharmacokinetic rationale.

Duration of Treatment: Why 28 Days Specifically?

The 28-day (4-week) treatment duration aligns with tissue repair cascade timelines. Weeks 1-2 establish anti-inflammatory environments via macrophage infiltration and phenotype switching. Weeks 2-4 activate and amplify tissue remodeling (angiogenesis, collagen turnover, nerve fiber regeneration initiation). By day 28, these processes are fully established and self-sustaining. Further continuous dosing beyond 4 weeks shows diminishing marginal tissue repair benefits, as the tissue-remodeling cascades plateau and require periods of consolidation rather than continued stimulation.

Body Weight Adjustments: Do They Apply?

No Weight-Based Dosing in Clinical Trials
ARA-290 clinical trials used fixed 4 mg dosing regardless of patient body weight. Trials included patients ranging from 45 kg to 150+ kg, all using identical 4 mg dosing. No weight-based dose adjustments were made or studied. This suggests either: body weight doesn't significantly affect ARA-290 pharmacokinetics, or the pharmacokinetic changes were insufficient to justify dose adjustments.

Possible Theoretical Rationale for Adjustment
Extremely obese individuals (BMI >40, body weight >150 kg) might theoretically require dose adjustments due to altered drug distribution in increased adipose tissue. However, without trial data supporting this, weight-based adjustments remain speculative. Current clinical practice uses fixed 4 mg regardless of weight.

Special Populations and Dosing Considerations

Elderly Patients
Phase II trials included patients aged 65-75 without special dose adjustments. No increased adverse events or reduced efficacy was observed in elderly populations. However, very elderly individuals (80+) with multiple comorbidities might warrant conservative approaches, though this reflects clinical judgment more than evidence.

Hepatic and Renal Impairment
Clinical trials did not specifically study patients with significant liver or kidney disease. ARA-290 undergoes hepatic metabolism and renal excretion. Patients with advanced hepatic or renal dysfunction might theoretically require dose reduction to prevent drug accumulation, but formal guidance is absent. Consultation with healthcare providers is essential in these populations.

Drug Interactions
No significant drug interactions with standard medications (NSAIDs, gabapentinoids, opioids, diabetes medications, cardiovascular drugs) have been reported. ARA-290 dosing doesn't require adjustment based on concurrent medications.

Trusted Research-Grade Sources

Below are the two vendors we recommend for research peptides — both publish independent third-party Certificates of Analysis (COAs) and ship internationally. Affiliate links: we earn a small commission at no extra cost to you (see Affiliate Disclosure).

Frequently Asked Questions

What is the standard ARA-290 dose?

Clinical Phase II trials established 4 mg once daily via subcutaneous self-injection for 28 consecutive days as the standard dose. This dose was selected based on pharmacokinetic and pharmacodynamic studies determining optimal innate repair receptor (IRR) pathway activation across all major clinical populations.

Can I use a lower dose like 2 or 3 mg?

While formal trials used 4 mg exclusively, some practitioners report using 2-3 mg for patients who are extremely sensitive, highly frail, or starting conservatively. Efficacy at lower doses is limited (preliminary reports suggest 2 mg produces ~50-60% of 4 mg benefits). Most clinical decisions favor standard 4 mg dosing given ARA-290's excellent safety profile.

How do I administer ARA-290 injections?

ARA-290 is administered via subcutaneous (SC) self-injection using a small needle (25-27 gauge, 5/8 inch). Inject at lower abdomen (2-3 inches lateral from midline), lateral thigh, or outer upper arm. Rotate injection sites to prevent localized irritation. Most patients successfully self-inject after a single healthcare provider demonstration.

Are there any weight-based dose adjustments?

No. Clinical trials used fixed 4 mg dosing regardless of patient body weight (ranging from 45 kg to 150+ kg). No weight-based adjustments were made or studied. Current clinical practice uses fixed 4 mg for all patients.

Can I skip doses or adjust the frequency?

Clinical protocols recommend daily dosing for the full 28-day cycle. Skipped doses interrupt sustained innate repair receptor activation and reduce overall efficacy. Extending duration is theoretically preferable to skipped doses if dose adjustment is needed. Discuss any planned modifications with your healthcare provider.

What if I accidentally miss an injection?

If you miss a daily injection, continue with the next scheduled dose. Do not double up by taking two doses the next day. Missing occasional doses reduces overall efficacy but doesn't represent a safety concern. Consistent adherence to daily dosing produces optimal outcomes.